Interim Report 2, 2024/2025
AUGUST 2024 – OCTOBER 2024
| Net sales | 2 977 (1 225) KSEK |
| Operating result before depreciation (EBITDA) | -2 790 (-4 037) KSEK |
| Net result | -3 669 (-5 375) KSEK |
| Earnings per share | -0.14 (-0.23) SEK |
| Gross margin | 55 (71) % |
MAY 2024 – OCTOBER 2024
| Net sales | 4 315 (3 951) KSEK |
| Operating result before depreciation (EBITDA) | -7 522 (-6 389) KSEK |
| Net result | -9 598 (-9 675) KSEK |
| Earnings per share | -0.37 (-0.47) SEK |
| Gross margin | 63 (74) % |
IN SHORT
- Sales grew significantly in Q2 vs. the same period last year, but only moderately YTD vs. the same period last year.
- Discounting on demo kits for our new distributors reduced the gross margin.
- Overall costs remain stable.
- The absolute key to transforming the company, both short-term and long-term, is a significant increase in sales, which the agreement with Altium promises to deliver.
For additional information, please contact:
Anders Månsson
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
